Gyre Therapeutics, Inc. (GYRE) Earnings History
Annual and quarterly earnings data from 2004 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 96.3% | 15.3% | 11.4% |
| 2023 | 95.9% | -59.3% | -81.9% |
| 2022 | 95.3% | 9.0% | 2.3% |
| 2021 | -4.5% | -1141.0% | -1198.3% |
| 2020 | 56.3% | -273.9% | -265.1% |
Download Data
Export GYRE earnings history in CSV or JSON format
Free sign-in required to download data
Gyre Therapeutics, Inc. (GYRE) Earnings Overview
As of March 1, 2026, Gyre Therapeutics, Inc. (GYRE) reported trailing twelve-month net income of $7M, reflecting +1.0% year-over-year growth. The company earned $0.06 per diluted share over the past four quarters, with a net profit margin of 0.1%.
Looking at the long-term picture, GYRE's historical earnings data spans multiple years. The company achieved its highest annual net income of $12M in fiscal 2024, representing a new all-time high.
Gyre Therapeutics, Inc. maintains positive profitability with a gross margin of 1.0%, operating margin of 0.2%, and net margin of 0.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ARGX ($923M net income, 0.4% margin), CANF (-$9M net income, -11.7% margin), AKTX (-$16M net income), GYRE has room to improve margins relative to the peer group. Compare GYRE vs ARGX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $12M | +113.0% | $16M | $0.05 | 11.4% | 15.3% |
| 2023 | -$93M | -4137.1% | -$67M | $-1.41 | -81.9% | -59.3% |
| 2022 | $2M | +102.6% | $9M | $0.03 | 2.3% | 9.0% |
| 2021 | -$88M | -58.3% | -$84M | $-2.87 | -1198.3% | -1141.0% |
| 2020 | -$56M | -0.7% | -$57M | $-2.93 | -265.1% | -273.9% |
| 2019 | -$55M | -83.6% | -$57M | $-4.41 | - | - |
| 2018 | -$30M | -39.4% | -$34M | $-2.68 | -500916.7% | -563700.0% |
| 2017 | -$22M | -27.2% | -$22M | $-6.30 | -2118.0% | -2143.6% |
| 2016 | -$17M | -14.8% | -$20M | $-21.76 | -4246.9% | -5117.3% |
| 2015 | -$15M | +54.7% | -$14M | $-49.99 | -843.5% | -788.7% |
See GYRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GYRE Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GYRE vs AGIO
See how GYRE stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is GYRE growing earnings?
GYRE EPS of $0.06 reflects slowing growth at +1.0%, below the 5-year CAGR of N/A. TTM net income is $7M. Expansion rate has moderated.
What are GYRE's profit margins?
Gyre Therapeutics, Inc. net margin is +0.1%, with operating margin at +0.2%. Below-average margins reflect competitive or cost pressures.
How consistent are GYRE's earnings?
GYRE earnings data spans 2004-2024. The current earnings trend is +1.0% YoY. Historical data enables comparison across business cycles.